ES2952139T3 - Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo - Google Patents

Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo Download PDF

Info

Publication number
ES2952139T3
ES2952139T3 ES20706332T ES20706332T ES2952139T3 ES 2952139 T3 ES2952139 T3 ES 2952139T3 ES 20706332 T ES20706332 T ES 20706332T ES 20706332 T ES20706332 T ES 20706332T ES 2952139 T3 ES2952139 T3 ES 2952139T3
Authority
ES
Spain
Prior art keywords
cyfra21
flt3l
colorectal cancer
areg
precancerous stage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20706332T
Other languages
English (en)
Spanish (es)
Inventor
Rodriguez Ana Carmen Martin
Palacios Rosa Perez
Arranz Rocío Arroyo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Marker Discovery SL AMADIX
Original Assignee
Advanced Marker Discovery SL AMADIX
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Marker Discovery SL AMADIX filed Critical Advanced Marker Discovery SL AMADIX
Application granted granted Critical
Publication of ES2952139T3 publication Critical patent/ES2952139T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES20706332T 2019-03-01 2020-02-28 Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo Active ES2952139T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382157 2019-03-01
EP19382156 2019-03-01
PCT/EP2020/055277 WO2020178172A1 (en) 2019-03-01 2020-02-28 Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof

Publications (1)

Publication Number Publication Date
ES2952139T3 true ES2952139T3 (es) 2023-10-27

Family

ID=69631636

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20706332T Active ES2952139T3 (es) 2019-03-01 2020-02-28 Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo

Country Status (10)

Country Link
US (1) US20220276249A1 (https=)
EP (1) EP3931571B1 (https=)
JP (2) JP2022522803A (https=)
KR (1) KR102769007B1 (https=)
CN (1) CN113785199B (https=)
AU (1) AU2020230963B2 (https=)
CA (1) CA3131729A1 (https=)
ES (1) ES2952139T3 (https=)
MX (1) MX2021010451A (https=)
WO (1) WO2020178172A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952139T3 (es) * 2019-03-01 2023-10-27 Advanced Marker Discovery S L Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo
WO2021185982A1 (en) * 2020-03-19 2021-09-23 Advanced Marker Discovery S.l. Protein signature for screening general population for colorectal cancer and/or pre-cancerous stage thereof
CA3202255A1 (en) 2020-12-21 2022-06-30 Hayley WARSINSKE Markers for the early detection of colon cell proliferative disorders
KR102900859B1 (ko) * 2021-12-31 2025-12-17 주식회사 이노제닉스 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005014386D1 (de) * 2004-12-23 2009-06-18 Roche Diagnostics Gmbh Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
CN101896817A (zh) * 2007-12-10 2010-11-24 霍夫曼-拉罗奇有限公司 用于结直肠癌的标记物组
CN103140760B (zh) * 2010-07-14 2016-01-27 联邦科学与工业研究组织 结肠直肠癌的诊断
US20140220006A1 (en) * 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Lung cancer biomarkers
US20160291025A1 (en) * 2013-09-18 2016-10-06 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
JP6339399B2 (ja) * 2014-03-28 2018-06-06 学校法人北里研究所 卵巣明細胞腺癌細胞の検出方法、卵巣明細胞腺癌診断薬、卵巣明細胞腺癌診断用プライマー、卵巣明細胞腺癌診断用キット、及び卵巣明細胞腺癌診断用プローブ
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
JP2018136122A (ja) * 2015-05-29 2018-08-30 国立研究開発法人国立がん研究センター 膵がんを診断するための血漿バイオマーカーパネル
US20180160885A1 (en) * 2016-12-13 2018-06-14 Prosper Abitbol Endoscopy based medical devices, methods, and innovations
KR102018205B1 (ko) * 2017-07-24 2019-09-05 (주) 바이오인프라생명과학 대장암 진단용 조성물 및 상기 조성물을 이용한 대장암 진단 방법
US10968583B2 (en) * 2017-07-26 2021-04-06 David E. Lambert Reflective road marker
ES2952139T3 (es) * 2019-03-01 2023-10-27 Advanced Marker Discovery S L Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo
WO2021185982A1 (en) * 2020-03-19 2021-09-23 Advanced Marker Discovery S.l. Protein signature for screening general population for colorectal cancer and/or pre-cancerous stage thereof

Also Published As

Publication number Publication date
US20220276249A1 (en) 2022-09-01
AU2020230963A1 (en) 2021-09-30
CN113785199A (zh) 2021-12-10
EP3931571B1 (en) 2023-06-07
JP2022522803A (ja) 2022-04-20
BR112021017248A2 (pt) 2021-11-09
EP3931571C0 (en) 2023-06-07
KR102769007B1 (ko) 2025-02-14
CA3131729A1 (en) 2020-09-10
JP2025038186A (ja) 2025-03-18
WO2020178172A1 (en) 2020-09-10
EP3931571A1 (en) 2022-01-05
KR20210134946A (ko) 2021-11-11
AU2020230963B2 (en) 2026-03-12
MX2021010451A (es) 2021-12-10
CN113785199B (zh) 2024-02-09

Similar Documents

Publication Publication Date Title
ES2952139T3 (es) Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo
Humphries et al. Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer
ES2362512T3 (es) Anexina para averiguar el riesgo de un cáncer.
ES2772701T3 (es) Uso de nucleosomas libres de células como biomarcadores en muestras de esputo
ES2634629T3 (es) Integrina alfa-V-beta 6 para el diagnóstico/pronóstico del carcinoma colorrectal
Aydin et al. Nucleosome assembly protein 1-like 1 (NAP1L1) in colon cancer patients: a potential biomarker with diagnostic and prognostic utility.
WO2010136629A1 (es) Métodos para el diagnóstico o pronóstico del cáncer colorrectal
CN116256521B (zh) 一种用于肠癌诊断的粪便外泌体蛋白的标志物及其应用
ES2436667B1 (es) Suero biomarcador para diagnosticar el cáncer colorrectal
US20230204584A1 (en) Protein signature for screening general population for colorectal cancer and/or pre-cancerous stage thereof
RU2830580C2 (ru) Белковая сигнатура для диагностики колоректального рака или его предраковой стадии
BR112021017248B1 (pt) Método in vitro para o diagnóstico de câncer colorretal e/ou um seu estágio pré- canceroso, usos in vitro da combinação de [flt3l e cyfra21-1] e da combinação de da combinação de [flt3l e cyfra21-1 e areg], ou [flt3l e cyfra21-1 e areg e erbb4], ou {flt3l e cyfra21-1 e areg e clec2c] em uma amostra biológica obtida do paciente,e uso de um kit de partes
US20160003827A1 (en) Method and apparatus of aiding detection of surface abnormality in the oesophagus
ES3032494T3 (en) Biomarkers for detecting cancer
JP2021038990A (ja) 大腸がん罹患のリスクを評価するための方法
JP5872285B2 (ja) 腎がん血中マーカー
Ibrahim et al. Serum Osteoprotegerin (OPG) as a Potential Biomarker for Disease Activity in Ulcerative Colitis
JP7660077B2 (ja) 診断方法
CN121713068A (zh) 癌症的检测辅助方法以及检测试剂盒
ÖzGeker et al. Research Article The Role of Fecal Calprotectin in Evaluating Intestinal Involvement of Behçet’s Disease
CN110632307A (zh) Suclg2自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN110780073A (zh) Spanxn3自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN110632318A (zh) Tpm3自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN110632316A (zh) Psrc1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN110596388A (zh) Aamp自身抗体检测试剂在制备肺癌筛查试剂盒中的用途